Premium
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LARGE B‐CELL LYMPHOMA: RESULTS OF A NORDIC PHASE 2 STUDY
Author(s) -
Leppä S,
Jørgensen J,
KarjalainenLindsberg ML,
Beiske K,
Nørgaard P,
Drott K,
Pasanen A,
Karihtala K,
Mannisto S,
Wold B,
Brodtkorb M,
Fagerli UnnM,
Larsen T. S,
Munksgaard L,
Fluge Ø,
Jyrkkiö S,
Brown P. d. N,
Holte H
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.27_2879
Subject(s) - medicine , international prognostic index , vincristine , rituximab , oncology , etoposide , diffuse large b cell lymphoma , lymphoma , chop , cyclophosphamide , prednisone , cytarabine , chemotherapy